Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses-Reference-Cited by-同舟云学术

Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses

Published:2023-11-29 Issue:12 Volume:16 Page:1201-1209
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Goulooze Sebastiaan C.¹,Vis Peter W.¹,Krekels Elke H.J.²,Knibbe Catherijne A.J.²³

Affiliation:

1. LAP&P Consultants BV, Leiden, The Netherlands

2. Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

3. Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2023.2288171

Reference76 articles.

1. Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis

2. European Medicines Agency. Evidence of harm from off-label or unlicensed medicines in children [Internet]. EMEA/126327/2004. 2004 [cited 2023 Jan 24]. Available from: https://www.ema.europa.eu/en/documents/other/evidence-harm-label-unlicensed-medicines-children_en.pdf.

3. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population

4. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital

5. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital